Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,507.47
(
0.45%
)
US TECH 100
29,091.20
(
1.36%
)
Dow Jones
50,456.40
(
-0.24%
)
Brent Oil
96.98
(
-4.15%
)
Bitcoin
76,392.25
(
-1.14%
)
News Focus
News Focus
Post# of 46420
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Jagman

Send PM Follow Ignore
Followers 63
Posts 14414
Boards Moderated 0
Alias Born 07/19/2003

Jagman

Re: Realperson post# 45973

Wednesday, 08/31/2011 7:13:21 AM

Wednesday, August 31, 2011 7:13:21 AM

Post# of 46420
"Even though Aeterna Zentaris out-licensed the rights to perifosine to Keryx Biopharmaceuticals (Nasdaq: KERX ) , I still think it has potential to contribute more to the bottom line than AEZS-130, which Aeterna Zentaris owns entirely. Only about 6,000 adults are diagnosed with AGHD every year."







Short-term flipping only, IMO!!!

Note: My comments on companies
are usually my opinion of long term success (years). The PPS may go
up or down greatly in the meantime depending on the number of
greedy suckers with money.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today